IP Library › Granted Patent US 8,372,420
Granted Patent B2
US 8,372,420 · App. 12/553,744 · Granted Feb 12, 2013

Compositions and methods for coating medical implants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,372,420
App. No.
12/553,744
Granted
Feb 12, 2013
Kind
B2
Abstract

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Claims (27)

1. An infection-resistant vascular access catheter, wherein the catheter comprises 0.1 μg to 1 mg fluoropyrimidine per mm 2 of surface area of the portion of the catheter to which the fluoropyrimidine is applied or incorporated, wherein the catheter releases the fluoropyrimidine in an amount effective to reduce or inhibit the likelihood of infection associated with the implantation of the catheter in a subject, and wherein the catheter does not release the fluoropyrimidine in an amount effective for the treatment of cancer in the subject that receives the vascular access catheter.

2. The catheter according to claim 1 wherein said catheter is covered or coated in whole or in part with a composition comprising the fluoropyrimidine.

3. The catheter according to claim 2 wherein said fluoropyrimidine is 5-fluorouracil.

4. The catheter according to claim 2 wherein said composition further comprises a polymer.

5. The catheter according to claim 4 wherein said polymer is a non-biodegradable polymer.

6. The catheter according to claim 4 wherein said polymer is polyurethane.

7. The catheter according to claim 6 , wherein the polyurethane is poly(carbonate urethane), poly(ester urethane), or poly(ether urethane).

8. The catheter according to claim 4 , wherein the polymer is selected from polyurethanes, acrylic or methacrylic copolymers, cellulose-derived polymers, and blends thereof.

9. The catheter of claim 2 , wherein said fluoropyrimidine is floxuridine.

10. The catheter according to claim 1 wherein said fluoropyrimidine is 5-fluorouracil.

11. The catheter according to claim 1 comprising 1 μg to 50 μg fluoropyrimidine per mm 2 of surface area of the portion of the catheter to which the fluoropyrimidine is applied or incorporated.

12. The catheter according to claim 1 comprising 1.0 μg to 250 mg fluoropyrimidine.

13. The catheter according to claim 1 comprising 10 μg to 25 mg fluoropyrimidine.

14. The catheter according to claim 1 further comprising a second anti-infective agent.

15. The catheter of claim 14 , wherein the second anti-infective agent is an antibiotic agent or an antifungal agent.

16. The catheter of claim 1 , further comprising an antithrombotic or antiplatelet agent.

17. The catheter of claim 16 , wherein the antithrombotic agent or antiplatelet agent is heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, or tissue plasminogen activator.

18. The catheter according to claim 1 , wherein the catheter is a central venous catheter.

19. The catheter according to claim 1 wherein the catheter is a vascular infusion catheter.

20. The catheter according to claim 1 , wherein the catheter is a hemodialysis catheter.

21. The catheter according to claim 20 , wherein the bacterial infection is antibiotic resistant.

22. The catheter according to claim 1 , wherein the fluoropyrimidine is present in an amount effective to reduce or inhibit bacterial infection associated with the catheter.

23. The catheter according to claim 1 , wherein the catheter releases the fluoropyrimidine in concentrations effective to reduce or inhibit infection associated with the catheter for a period ranging from 1 to 30 days.

24. An infection-resistant central venous catheter coated with a composition comprising polyurethane, nitrocellulose, and 5-fluorouracil in an amount of 0.1 μg to 1 mg per mm2 of surface area of the portion of the catheter to which 5-fluorouracil is applied or incorporated, wherein the catheter released 5-fluorouracil in an amount effective to reduce infection associated with the catheter, and wherein the amount of 5-fluorouracil released from the catheter is ineffective to treat cancer.

25. The central venous catheter of claim 24 , wherein the central venous catheter is composed of polyurethane.

26. The central venous catheter of claim 24 , wherein the central venous catheter is coated with the composition comprising polyurethane, nitrocellulose and 5-fluorouracil on its exterior surface.

27. The catheter of claim 1 , wherein said fluoropyrimidine is floxuridine.